NOVOZYMES A/S/S (OTCMKTS:NVZMY) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of NOVOZYMES A/S/S (OTCMKTS:NVZMY) from a hold rating to a buy rating in a research note published on Wednesday, Zacks.com reports. They currently have $57.00 target price on the biotechnology company’s stock.

According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “

Several other research firms also recently issued reports on NVZMY. Goldman Sachs Group downgraded shares of NOVOZYMES A/S/S from a buy rating to a sell rating in a report on Wednesday, April 1st. Credit Suisse Group lowered shares of NOVOZYMES A/S/S from an outperform rating to an underperform rating in a research note on Tuesday, May 12th. Finally, ValuEngine upgraded shares of NOVOZYMES A/S/S from a sell rating to a hold rating in a research note on Saturday, March 14th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $57.00.

Shares of NVZMY opened at $51.39 on Wednesday. The company has a 50 day moving average of $48.07 and a two-hundred day moving average of $48.55. The company has a quick ratio of 0.76, a current ratio of 1.29 and a debt-to-equity ratio of 0.23. NOVOZYMES A/S/S has a twelve month low of $37.99 and a twelve month high of $55.51. The company has a market cap of $15.30 billion, a price-to-earnings ratio of 32.01, a price-to-earnings-growth ratio of 22.84 and a beta of 0.70.

NOVOZYMES A/S/S (OTCMKTS:NVZMY) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $0.42 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.42. NOVOZYMES A/S/S had a return on equity of 26.90% and a net margin of 21.08%. The firm had revenue of $558.75 million during the quarter. On average, sell-side analysts expect that NOVOZYMES A/S/S will post 1.65 EPS for the current year.

About NOVOZYMES A/S/S

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry.

Further Reading: Limitations of the P/E Growth ratio

Get a free copy of the Zacks research report on NOVOZYMES A/S/S (NVZMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NOVOZYMES A/S/S (OTCMKTS:NVZMY)

Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.